Close
Study: Dogs With Mammary Carcinoma

This is a funded trial for the evaluation of a therapeutic option (an FDA conditionally approved drug) for treatment of mammary carcinoma. All diagnostic tests (including biopsy for confirmatory histopathology), study drug, rescue medication and follow-up exams will be paid for by the study sponsor.

Dogs meeting all of these criteria will be considered for the study:

  • Female dogs of any age, weight or breed
  • Dogs with at least one measurable lesion with a longest diameter (LD) of ≥ 10 mm and in whom curative intent surgery is not feasible
  • No prior chemotherapy, radiation therapy, hormonal or biological therapy directed at the target lesion is or has been initiated
  • Long-term NSAIDs and steroids are permitted if the dog has been on them for at least 30 days before screening; short-term NSAIDs and steroids must have been discontinued at least 30 days before screening. Therefore, if the dog is NOT on an NSAID, do not initiate therapy with this category of drugs. Tramadol can be used if analgesia is needed.
  • Life expectancy, in the primary care veterinarian and investigator’s opinions, is greater than 1 month with treatment
Trial Details:

Dogs will be randomized to receive the new investigational drug or placebo at a 2:1 ratio. Dogs that are randomized to placebo and/or progress during the 4-cycle treatment period will be offered rescue treatment by the investigator, as determined by the protocol.

Florida Participation

For more information or to enroll your client and patient in this study, please contact Drs. Curtis Kane or Jen Coyle, or technicians Lexy Julian or Rob Guevara, CVT in our Tampa hospital at (813) 933-8944.

Michigan Participation

For more information or to enroll your client and patient in this study, please contact Dr. Angela Kozicki, or Jamie Hamilton, LVT at our Southfield hospital at (248) 354-6640.